Neogenomics

Neogenomics Gross Profit

The Gross Profit of Neogenomics (NEO) as of Nov 18, 2026 is 282.54 M USD. In the previous year, Gross Profit was 290.10 M USD — a change of -2.61% (lower).

Gross Profit

282.54 MUSD

YoY

-2.61%

Last updated:

Gross Profit of Neogenomics is 2025 282.54 M USD. Gross Profit of Neogenomics was 2024 290.10 M USD. It decreases by -2.61% lower compared to the previous year.

The Neogenomics Gross Profit history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Gross Profit
Date
Gross Profit
Jan 1, 2018
127.27 M USD
Jan 1, 2019
196.84 M USD
Jan 1, 2020
185.89 M USD
Jan 1, 2021
187.06 M USD
Jan 1, 2022
187.90 M USD
Jan 1, 2023
244.60 M USD
Jan 1, 2024
290.10 M USD
Jan 1, 2025
282.54 M USD
The Neogenomics Gross Profit history
YEARGross ProfitYoY
282.54 MUSD-2.61%
290.10 MUSD+18.60%
244.60 MUSD+30.18%
187.90 MUSD+0.45%
187.06 MUSD+0.63%
185.89 MUSD-5.56%
196.84 MUSD+54.67%
127.27 MUSD+24.82%
101.96 MUSD-7.63%
110.38 MUSD+152.26%
43.76 MUSD+7.47%
40.71 MUSD+28.29%
31.74 MUSD+18.26%
26.84 MUSD+38.13%
19.43 MUSD+23.09%
15.78 MUSD+3.73%
15.22 MUSD+42.72%
10.66 MUSD+78.22%
5.98 MUSD+60.94%
3.72 MUSD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Neogenomics Revenue

Neogenomics Revenue, EBIT, Net Income

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details
Date
Revenue
EBIT
Net Income
Jan 1, 2023
591.64 M USD
-107.74 M USD
-87.97 M USD
Jan 1, 2024
660.57 M USD
-92.11 M USD
-78.73 M USD
Jan 1, 2025
727.33 M USD
-66.08 M USD
-108.03 M USD
Jan 1, 2026 (e)
808.20 M USD
36.00 M USD
25.84 M USD
Jan 1, 2027 (e)
886.92 M USD
54.92 M USD
39.85 M USD
Jan 1, 2028 (e)
971.97 M USD
70.38 M USD
51.08 M USD
Jan 1, 2029 (e)
1.03 B USD
108.05 M USD
87.39 M USD
Jan 1, 2030 (e)
1.11 B USD
125.84 M USD
102.59 M USD

Neogenomics Margins

Neogenomics stock margins

The Neogenomics margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Neogenomics. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Neogenomics.
  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details
Date
Gross margin
EBIT margin
Profit margin
Jan 1, 2023
41.34 %
-18.21 %
-14.87 %
Jan 1, 2024
43.92 %
-13.94 %
-11.92 %
Jan 1, 2025
38.85 %
-9.09 %
-14.85 %
Jan 1, 2026 (e)
38.85 %
4.45 %
3.20 %
Jan 1, 2027 (e)
38.85 %
6.19 %
4.49 %
Jan 1, 2028 (e)
38.85 %
7.24 %
5.26 %
Jan 1, 2029 (e)
38.85 %
10.50 %
8.49 %
Jan 1, 2030 (e)
38.85 %
11.32 %
9.23 %

Neogenomics Stock analysis

What does Neogenomics do? Neogenomics Inc. is a leading company in the field of personalized medicine, based in Fort Myers, Florida. It offers integrated diagnostics and pharmaceutical services for oncology and gene therapy, with a focus on providing accurate diagnosis for cancer patients. Neogenomics is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Neogenomics stock

Gross Profit of Neogenomics is 282.54 M USD in 2025.

Gross Profit of Neogenomics changed from 290.10 M USD to 282.54 M USD, representing a -2.61% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Gross Profit Neogenomics since 2006 – with annual values, charts, and detailed analysis.

Gross Profit is the revenue remaining after deducting the cost of goods sold. It shows how efficiently a company uses its resources to produce goods or services.

Gross Profit's USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Gross Profit's Neogenomics historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Income Statement — Neogenomics

All Key Metrics — Neogenomics